B. W. Van-tassell, R. A. Arena, and S. Toldo, Enhanced interleukin-1 activity contributes to exercise intolerance in patients with systolic heart failure, PLoS One, vol.7, p.33438, 2012.

I. Guillen, M. Blanes, M. J. Gomez-lechon, and J. V. Castell, Cytokine signaling during myocardial infarction: sequential appearance of IL-1beta and IL-6, Am J Physiol, vol.269, pp.229-264, 1995.

A. Herskowitz, S. Choi, A. A. Ansari, and S. Wesselingh, Cytokine mRNA expression in postischemic/ reperfused myocardium, Am J Pathol, vol.146, pp.419-447, 1995.

M. Nian, P. Lee, N. Khaper, and P. Liu, Inflammatory cytokines and postmyocardial infarction remodeling, Circ Res, vol.94, pp.1543-53, 2004.

P. C. Westman, M. J. Lipinski, and D. Luger, Inflammation as a driver of adverse left ventricular remodeling after acute myocardial infarction, J Am Coll Cardiol, vol.67, pp.2050-60, 2016.

B. W. Van-tassell, S. Toldo, E. Mezzaroma, and A. Abbate, Targeting interleukin-1 in heart disease, Circulation, vol.128, pp.1910-1933, 2013.

A. Abbate, B. W. Van-tassell, and I. M. Seropian, Interleukin-1beta modulation using a genetically engineered antibody prevents adverse cardiac remodelling following acute myocardial infarction in the mouse, Eur J Heart Fail, vol.12, pp.319-341, 2010.

A. M. Owyang, H. Issafras, and J. Corbin, XOMA 052, a potent, high-affinity monoclonal antibody for the treatment of IL-1beta-mediated diseases, MAbs, vol.3, pp.49-60, 2011.

M. K. Roell, H. Issafras, and R. J. Bauer, Kinetic approach to pathway attenuation using XOMA 052, a regulatory therapeutic antibody that modulates interleukin-1beta activity, J Biol Chem, vol.285, pp.20607-20621, 2010.

V. Richard, N. Kaeffer, C. Tron, and C. Thuillez, Ischemic preconditioning protects against coronary endothelial dysfunction induced by ischemia and reperfusion, Circulation, vol.89, pp.1254-61, 1994.

O. Henri, C. Pouehe, and M. Houssari, Selective stimulation of cardiac lymphangiogenesis reduces myocardial edema and fibrosis leading to improved cardiac function following myocardial infarction, Circulation, vol.133, pp.1484-97, 2016.
URL : https://hal.archives-ouvertes.fr/inserm-02296561

P. Mulder, S. Barbier, and A. Chagraoui, Longterm heart rate reduction induced by the selective I(f) current inhibitor ivabradine improves left ventricular function and intrinsic myocardial structure in congestive heart failure, Circulation, vol.109, pp.1674-1683, 2004.

P. Mulder, V. Mellin, and J. Favre, Aldosterone synthase inhibition improves cardiovascular function and structure in rats with heart failure: a comparison with spironolactone, Eur Heart J, vol.29, pp.2171-2180, 2008.

D. L. Mann, J. J. Mcmurray, and M. Packer, Targeted anticytokine therapy in patients with chronic heart failure: results of the Randomized Etanercept Worldwide Evaluation (RENEWAL), Circulation, vol.109, pp.1594-602, 2004.

S. Deftereos, G. Giannopoulos, and V. Panagopoulou, Anti-inflammatory treatment with colchicine in stable chronic heart failure: a prospective, randomized study, J Am Coll Cardiol HF, vol.2, pp.131-138, 2014.

A. Abbate, F. N. Salloum, and E. Vecile, Anakinra, a recombinant human interleukin-1 receptor antagonist, inhibits apoptosis in experimental acute myocardial infarction, Circulation, vol.117, pp.2670-83, 2008.

F. N. Salloum, V. Chau, and A. Varma, Anakinra in experimental acute myocardial infarction: does dosage or duration of treatment matter? Cardiovasc, Drugs Ther, vol.23, pp.129-164, 2009.

A. Abbate, M. C. Kontos, and N. A. Abouzaki, Comparative safety of interleukin-1 blockade with anakinra in patients with ST-segment elevation acute myocardial infarction (from the VCU-ART and VCU-ART2 pilot studies), Am J Cardiol, vol.115, pp.288-92, 2015.

A. Abbate, M. C. Kontos, and J. D. Grizzard, Interleukin-1 blockade with anakinra to prevent adverse cardiac remodeling after acute myocardial infarction (Virginia Commonwealth University Anakinra Remodeling Trial

, Am J Cardiol, vol.105, pp.1371-1378, 2010.

A. Abbate, B. W. Van-tassell, and G. Biondi-zoccai, Effects of interleukin-1 blockade with anakinra on adverse cardiac remodeling and heart failure after acute myocardial infarction

, Am J Cardiol, vol.111, pp.1394-400, 2013.

B. W. Van-tassell, I. M. Seropian, S. Toldo, E. Mezzaroma, and A. Abbate, Interleukin-1beta induces a reversible cardiomyopathy in the mouse, Inflam Res, vol.62, pp.637-677, 2013.

C. Kho, A. Lee, and R. J. Hajjar, Altered sarcoplasmic reticulum calcium cycling: targets for heart failure therapy, Nat Rev Cardiol, vol.9, pp.717-750, 2012.

H. H. Radeke, B. Meier, N. Topley, J. Floge, G. G. Habermehl et al., Interleukin 1-alpha and tumor necrosis factor-alpha induce oxygen radical production in mesangial cells, Kidney Int, vol.37, pp.767-75, 1990.

M. Yoshizumi, H. Kurihara, and T. Morita, Interleukin 1 increases the production of endothelin-1 by cultured endothelial cells, Biochem Biophys Res Commun, vol.166, pp.324-333, 1990.

P. Mulder, V. Richard, and G. Derumeaux, Role of endogenous endothelin in chronic heart failure: effect of long-term treatment with an endothelin antagonist on survival, hemodynamics, and cardiac remodeling, Circulation, vol.96, pp.1976-82, 1997.

S. Sakai, T. Miyauchi, M. Kobayashi, I. Yamaguchi, K. Goto et al., Inhibition of myocardial endothelin pathway improves long-term survival in heart failure, Nature, vol.384, pp.353-358, 1996.

M. Jain, D. A. Brenner, and L. Cui, Glucose-6-phosphate dehydrogenase modulates cytosolic redox status and contractile phenotype in adult cardiomyocytes, Circ Res, vol.93, pp.9-16, 2003.

G. M. Kuster, S. Lancel, and J. Zhang, Redoxmediated reciprocal regulation of SERCA and Na þ -Ca 2þ exchanger contributes to sarcoplasmic reticulum Ca 2þ depletion in cardiac myocytes, Free Radic Biol Med, vol.48, pp.1182-1189, 2010.

D. A. Siwik, P. J. Pagano, and W. S. Colucci, Oxidative stress regulates collagen synthesis and matrix metalloproteinase activity in cardiac fibroblasts

, Am J Physiol Cell Physiol, vol.280, pp.53-60, 2001.

W. Zhao, T. Zhao, Y. Chen, R. A. Ahokas, and Y. Sun, Oxidative stress mediates cardiac fibrosis by enhancing transforming growth factor-beta1 in hypertensive rats, Mol Cell Biochem, vol.317, pp.43-50, 2008.

T. C. Gillebert, D. Hert, S. G. Andries, L. J. Jageneau, A. H. Brutsaert et al., Intracavitary ultrasound impairs left ventricular performance: presumed role of endocardial endothelium, Am J Physiol, vol.263, pp.857-65, 1992.

L. Van-heerebeek, N. Hamdani, and M. L. Handoko, Diastolic stiffness of the failing diabetic heart: importance of fibrosis, advanced glycation end products, and myocyte resting tension, Circulation, vol.117, pp.43-51, 2008.

L. Van-heerebeek, A. Somsen, and W. J. Paulus, The failing diabetic heart: focus on diastolic left ventricular dysfunction, Curr Diab Rep, vol.9, pp.79-86, 2009.

M. M. El-omar, R. Lord, N. J. Draper, and A. M. Shah, Role of nitric oxide in posthypoxic contractile dysfunction of diabetic cardiomyopathy, Eur J Heart Fail, vol.5, pp.229-268, 2003.

G. A. Silberman, T. H. Fan, and H. Liu, Effect of NO donors on LV diastolic function in patients with severe pressure-overload hypertrophy, Matter CM, vol.121, pp.2396-401, 1999.

D. Fraccarollo, J. D. Widder, and P. Galuppo, Improvement in left ventricular remodeling by the endothelial nitric oxide synthase enhancer AVE9488 after experimental myocardial infarction, Circulation, vol.118, pp.818-845, 2008.

S. Serpillon, B. C. Floyd, and R. S. Gupte, Superoxide production by NAD(P)H oxidase and mitochondria is increased in genetically obese and hyperglycemic rat heart and aorta before the development of cardiac dysfunction. The role of glucose-6-phosphate dehydrogenase-derived NADPH, Am J Physiol Heart Circ Physiol, vol.297, pp.153-62, 2009.

P. Rosen and A. Osmers, Oxidative stress in young Zucker rats with impaired glucose tolerance is diminished by acarbose, Horm Metab Res, vol.38, pp.575-86, 2006.

M. Sauve, K. Ban, and M. A. Momen, Genetic deletion or pharmacological inhibition of dipeptidyl peptidase-4 improves cardiovascular outcomes after myocardial infarction in mice, Diabetes, vol.59, pp.1063-73, 2010.

J. E. Toblli, G. Cao, J. F. Giani, M. Angerosa, F. P. Dominici et al., Antifibrotic effects of pioglitazone at low doses on the diabetic rat kidney are associated with the improvement of markers of cell turnover, tubular and endothelial integrity, and angiogenesis, Kidney Blood Press Res, vol.34, pp.20-33, 2012.

K. Sekiguchi, X. Li, and M. Coker, Crossregulation between the renin-angiotensin system and inflammatory mediators in cardiac hypertrophy and failure, Cardiovasc Res, vol.63, pp.433-475, 2004.

H. Otani, The role of nitric oxide in myocardial repair and remodeling, Antioxid Redox Signal, vol.11, pp.1913-1941, 2009.

D. Luger, M. J. Lipinski, and P. C. Westman, Intravenously delivered mesenchymal stem cells: systemic anti-inflammatory effects improve left ventricular dysfunction in acute myocardial infarction and ischemic cardiomyopathy, Circ Res, vol.120, pp.1598-613, 2017.

G. Ozer, Z. Teker, and S. Cetiner, Serum IL-1, IL-2, TNFalpha and INFgamma levels of patients with type 1 diabetes mellitus and their siblings, J Pediatr Endocrinol Metab, vol.16, pp.203-213, 2003.

E. J. Van-asseldonk, P. C. Van-poppel, D. B. Ballak, R. Stienstra, M. G. Netea et al., One week treatment with the IL-1 receptor antagonist anakinra leads to a sustained improvement in insulin sensitivity in insulin resistant patients with type 1 diabetes mellitus, Clin Immunol, vol.160, pp.155-62, 2015.

M. A. Pfeffer, J. M. Pfeffer, C. Steinberg, and P. Finn, Survival after an experimental myocardial infarction: beneficial effects of long-term therapy with captopril, Circulation, vol.72, pp.406-418, 1985.

K. C. Wollert, R. Studer, V. Bulow, B. Drexler, and H. , Survival after myocardial infarction in the rat. Role of tissue angiotensin-converting enzyme inhibition, Circulation, vol.90, pp.2457-67, 1994.

, KEY WORDS cardiovascular function, heart failure, IL-1b, ischemia/reperfusion APPENDIX For an expanded Methods section and a supplemental figure, please see the online version of this article